NCT00788177View on ClinicalTrials.gov

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

PHASE3UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

March 31, 2012

Study Completion Date

December 31, 2012

Conditions
Age-related Macular Degeneration
Interventions
DRUG

Pegaptanib (Macugen®)

Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)

Trial Locations (1)

67063

RECRUITING

Department of Ophthalmology, Ludwigshafen hospital, Ludwigshafen

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Klinikum Ludwigshafen

OTHER